- Market Realist•52 minutes ago
In Russia, Teva Pharmaceutical has created a strong portfolio of about 300 products and has been extensively developing its research pipeline.
- PR Newswire•23 hours ago
DUBLIN, Sept. 29, 2016 /PRNewswire/ -- Allergan plc (AGN), today issued the following statement regarding ongoing litigation on patents related to NAMENDA XR® (memantine hydrochloride) extended release capsules following announcement of FDA final ANDA approval by Lupin. One of the licensed patent families covering Namenda XR has been held invalid by the Federal District Court for the District of Delaware. That decision is under appeal to the U.S. Court of Appeals for the Federal Circuit. The Company will defend the validity of these patents on appeal and believes that its arguments on appeal are substantial and meritorious.
Allergan plc (AGN)
NYSE - NYSE Real Time Price. Currency in USD
|Bid||231.25 x 100|
|Ask||232.50 x 500|
|Day's Range||229.61 - 238.13|
|52wk Range||195.50 - 322.68|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||21.97|
|Avg Vol (3m)||2,998,007|
|Dividend & Yield||N/A (N/A)|